{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:16:31Z","timestamp":1783332991538,"version":"3.54.6"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2025-A-16"],"award-info":[{"award-number":["2025-A-16"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancers other than pancreatic ductal adenocarcinoma (PDAC) are rare and heterogeneous, accounting for fewer than 5%\u20137% of all pancreatic cancers. These include acinar cell carcinoma, undifferentiated carcinoma, adenosquamous carcinoma, colloid carcinoma, neuroendocrine carcinoma (NEC), mixed neuroendocrine\u2013non-neuroendocrine neoplasm (MiNEN), and invasive intraductal papillary mucinous carcinoma (IPMC). Optimal treatment strategies, including sequencing and later-line options, remain unclear. Although nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and l-leucovorin (LV) is effective in gemcitabine-refractory PDAC, its role in these rare subtypes is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed nine patients with one of these rare subtypes who received nal-IRI plus 5-FU and LV between June 2020 and November 2024. Efficacy and safety were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included two cases each of IPMC and adenosquamous carcinoma, and one case each of colloid carcinoma, undifferentiated carcinoma, acinar cell carcinoma, NEC, and MiNEN. Partial responses were observed in four patients, including undifferentiated carcinoma, acinar cell carcinoma, NEC, and MiNEN, even among tumors refractory to gemcitabine- or platinum-based regimens. Disease control was achieved in seven patients (77.8%). The median progression-free survival was 6.8\u00a0months. Disease control exceeding 12\u00a0months was observed in three patients. Median overall survival from first-line therapy was not reached. Treatment-related toxicities were generally manageable, with neutropenia being the most common grade\u00a0\u2265\u00a03 adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nal-IRI plus 5-FU and LV showed antitumor activity and was tolerable among the nine patients analyzed in this study, suggesting it may be a therapeutic option in second- or later-line settings for rare pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag044","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:27:38Z","timestamp":1774009658000},"page":"858-864","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8771-824X","authenticated-orcid":false,"given":"Tomonao","family":"Taira","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Satake","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Amisaki","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhito","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-0095","authenticated-orcid":false,"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Mitsunaga","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2026070605422991000_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18063\/ghl.v2i1.243","article-title":"Pancreatic cancer: current situation and challenges","volume":"2","author":"Cheng","year":"2020","journal-title":"Gastroenterology & amp; Hepatology Letters"},{"key":"2026070605422991000_ref2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026070605422991000_ref3","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet."},{"key":"2026070605422991000_ref4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070605422991000_ref5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070605422991000_ref6","volume-title":"Clinical practice guidelines for pancreatic cancer 2025","author":"Society JP","year":"2025"},{"key":"2026070605422991000_ref7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026070605422991000_ref8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4251\/wjgo.v12.i8.833","article-title":"One size does not fit all for pancreatic cancers: a review on rare histologies and therapeutic approaches","volume":"12","author":"Niger","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"2026070605422991000_ref9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00535-023-01986-9","article-title":"Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan","volume":"58","author":"Sakakida","year":"2023","journal-title":"J Gastroenterol"},{"key":"2026070605422991000_ref10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s00535-022-01920-5","article-title":"The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry","volume":"57","author":"Satake","year":"2022","journal-title":"J Gastroenterol"},{"key":"2026070605422991000_ref11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00423-024-03506-6","article-title":"Histological variants of pancreatic ductal adenocarcinoma: a survival analysis","volume":"409","author":"Bengtsson","year":"2024","journal-title":"Langenbecks Arch Surg"},{"key":"2026070605422991000_ref12","doi-asserted-by":"publisher","first-page":"17588359241265213","DOI":"10.1177\/17588359241265213","article-title":"A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?","volume":"16","author":"Jesus","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"2026070605422991000_ref13","doi-asserted-by":"publisher","first-page":"102015","DOI":"10.1016\/j.eclinm.2023.102015","article-title":"NET-02: a randomised, non-comparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma","volume":"60","author":"McNamara","year":"2023","journal-title":"EClinicalMedicine."},{"key":"2026070605422991000_ref14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/MPA.0000000000001718","article-title":"Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens","volume":"50","author":"Takahashi","year":"2021","journal-title":"Pancreas."},{"key":"2026070605422991000_ref15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.pan.2022.09.236","article-title":"Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: a multicenter retrospective analysis","volume":"22","author":"Yoshida","year":"2022","journal-title":"Pancreatology."},{"key":"2026070605422991000_ref16","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1186\/s12885-020-07462-4","article-title":"Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study","volume":"20","author":"Imaoka","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/858\/67433235\/hyag044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/858\/67433235\/hyag044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:42:36Z","timestamp":1783330956000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/7\/858\/8530446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag044","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,20]]}}}